By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today said that it expects to raise approximately $17.6 million through a public offering of 4.2 million shares of its common stock priced at $4.50 per share.

The Madison, Wis.-based molecular diagnostics firm said that if the underwriters of the offering exercise the option to purchase an additional 630,000 shares, it would receive total net proceeds of around $20.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.